[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Boqué
C
C
Servicio de Hematología Clínica, Institut Català d'Oncologia, L'Hospitalet, Barcelona.
Grañena
A
A
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001781:Blood Component Removal; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D016044:Fusion Proteins, bcr-abl; D002066:Busulfan; D002945:Cisplatin; D007069:Ifosfamide; D006918:Hydroxyurea
Trasplante autólogo de progenitores hematopoyéticos en la leucemia mieloide crónica.